Arsho Salazar
Psychiatric/Mental Health · Pasadena, CANPI 1194298109
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 658 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $5,459, 2.1 times the $2,545 reported in 2021. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 658 payments — averaging $28.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$3K
- Teva Pharmaceuticals USA, Inc.$3K
- Alkermes, Inc.$3K
- Johnson & Johnson$3K
- Neurocrine Biosciences, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- plus $4K from 12 others
What the payments were for
- Food & beverage$18,51998%
- Education$3332%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 106 | $3,383 |
| Teva Pharmaceuticals USA, Inc. | 106 | $3,298 |
| Alkermes, Inc. | 105 | $2,580 |
| Johnson & Johnson | 77 | $2,540 |
| Neurocrine Biosciences, Inc. | 43 | $1,524 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 63 | $1,378 |
| Otsuka America Pharmaceutical, Inc. | 43 | $1,140 |
| E.r. Squibb & Sons, L.L.C. | 30 | $845 |
| Indivior Inc. | 29 | $617 |
| Idorsia Pharmaceuticals US Inc | 16 | $425 |
| Axsome Therapeutics, Inc. | 8 | $288 |
| AbbVie | 13 | $284 |
| Lundbeck LLC | 8 | $219 |
| Noven Therapeutics, LLC | 6 | $130 |
| Braeburn Inc. | 1 | $119 |
| Luye Pharma (USA) Ltd. | 2 | $42 |
| Tempus AI, Inc | 1 | $21 |
| Gilead | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$980
- Fanapt$725
- INVEGA SUSTENNA$712
- INGREZZA$631
- INVEGA TRINZA$587
- CAPLYTA$357
- ARISTADA INITIO$245
- AUSTEDO$245
- UZEDY$242
- ABILIFY MAINTENA$240
- INVEGA$125
- SPRAVATO$125
- ABILIFY ASIMTUFII$125
- COBENFY$124
- Auvelity$122
- Austedo XR$122
- QUVIVIQ$121
- BRIXADI$119
How this compares
$18,853 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $102,260 |
| AristadaAripiprazole Lauroxil | 25 | $83,374 |
| Invega SustennaPaliperidone Palmitate | 20 | $71,541 |
| FanaptIloperidone | 25 | $60,912 |
| RybelsusSemaglutide | 42 | $41,357 |
| LybalviOlanzapine/Samidorphan Malate | 25 | $40,219 |
| RexultiBrexpiprazole | 16 | $23,775 |
| QuviviqDaridorexant Hcl | 31 | $13,543 |
| BelsomraSuvorexant | 21 | $9,447 |
| Clozapine | 74 | $6,344 |
| Lurasidone Hcl | 13 | $3,710 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $3,076 |
| Vilazodone Hcl | 26 | $2,965 |
| Asenapine Maleate | 17 | $2,358 |
| Bupropion XlBupropion Hcl | 55 | $1,677 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada, Lybalvi | $2,580 | $123,59250 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,524 | $102,26012 claims |
| Johnson & JohnsonInvega Sustenna | $2,540 | $71,54120 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $3,383 | $60,91225 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,140 | $23,77516 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $425 | $13,54331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Pasadena
- Jonathan LlamasPasadena$31K
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
- Sarah KoLos Angeles$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.